Recently, the Boehringer Ingelheim company's annual press conference held today announced results for 2009, the company was growing and achieving Sell The amount of 12.7 billion euros, up 9.7% over the previous year (2008 sales of 11.6 billion euros). Even if not considering the favorable exchange rate factor, again higher than the global growth rate Pharmacy 6.7% average market growth rate. This means that Boehringer Ingelheim for the tenth consecutive year of growth above the market average, as in 2009 the world's top 15 largest pharmaceutical companies in the fastest growing companies.
2009, the Boehringer Ingelheim's most important and largest business unit? Prescription drug business accounts business for more than 80% of the total sales of more than 10 billion euros, a growth rate in euros, 10.4%. Among the core products prescription drug Spiriva ® (chronic obstructive pulmonary disease), Harold ® (benign prostate growth), the United States Cassels ® (anti-hypertension) and Sen Fuluo ® (Parkinson's / restless leg syndrome) and total sales of 60 million euros, growth of 17.5%.
Boehringer Ingelheim's own health Drugs (CHC) business is also unfavorable economic situation was the increase in sales of 1.3 billion euros, a growth rate in euros, 5.9%.
Animal health business, Boehringer Ingelheim in 2009 achieved sales of 610 million euros, an increase of 30.6%. One of the most important growth driver of the pigs from their own vaccine products, including core products Yin grid made CircoFLEX ® (porcine circovirus vaccine).
Geographical point of view, Boehringer Ingelheim in all business areas have once again won the business growth. 3A Region (Asia, Greater Asia, Africa) performed exceptionally well, total sales of 1.8 billion euros, a growth rate in euros, 15.2%. Those fast-growing markets such as Brazil, Russia, India and China will Boehringer Ingelheim opportunities for future business growth, companies are increasing investment in these markets.
Boehringer Ingelheim is a leading biotechnology companies. The part of the business in 2009 and last year sales of approximately the same, about 533 million euros (-2.9%). For the global pharmaceutical and biotechnology industry clients in product development, the company intends to further expand for small biotech companies and emerging markets in China, the service areas.
From Boehringer Ingelheim research and development on their own line of view, including anticoagulant therapy, female libido, type 2 Diabetes , In particular tumor in late stage development compounds, again in 2009, provides a strong data. New oral anticoagulants such as direct inhibitors Dabigatran etexilate (PRADAXA), the company is developing for the new stroke prevention in patients with atrial fibrillation indication. GIROSA (class color Lin F) for the treatment of women with low sexual desire is also further developed. Two tumor compounds were also made good progress, mainly used Lung Cancer , Breast cancer, ovarian cancer and colon cancer. BIBW2992 has entered Phase III clinical stage, it is the first generation inhibitor of tyrosine in urine. Vasomotion inhibitor belonging to the BIBW1120 also in Phase III clinical stage. Is dipeptidyl peptidase -4 inhibitor of diabetes drugs Linaliptin the three listed clinical has been completed.
Boehringer Ingelheim in 2009, it is also the 125th anniversary of the company, when once again invested heavily in its future. Company R & D costs for new drugs to 22 million euros, 100 million euros over the previous year, prescription drug business that will 21% of sales invested in research and development.
"In 2009, we had more challenging for the fiscal year 2010, well prepared," Executive Chairman of the Board, responsible for research and professor of medicine Bo Ande said. Boehringer Ingelheim look forward to fiscal year 2010 net sales were flat with last year, which means that the U.S. market, a number of important product FLOMAX ®, Sen Fuluo ®, CATAPRESAN ® TTS imitation competition brought about by sales losses, expected other products will be increased to compensate.
Boehringer Ingelheim has for the future to lay the foundation for sustainable growth, Boan De professor said: "We expect the listing of new drugs in 2010, the company will bring another successful stage of development? These drugs can for the patients to provide reliable treatment of disease control benefits. " I am an expert from China Toys Suppliers, usually analyzes all kind of industries situation, such as copper bay window , laser welding plastics.
Related Articles -
copper bay window, laser welding plastics,
|
